UNSPSC 51141591: Donepezil oxalate

This classification denotes an acetylcholinesterase inhibitor C24H29NO3.C2H2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SLF7M28SI5, chemically known as 1h-inden-1-one, 2,3-dihydro-5,6-dimethoxyl-2-((1-(phenylmethyl)-4-piperidinyl)methyl)-, ethanedoioate (1:1), but more generally known as donepezil oxalate, which bears US NIH Compound Identifier 11397232. Most nations, for tariff and trade purposes, schedule donepezil oxalate under HS 29333999 and SITC 51574.

As of Q4 2014, DONEPEZIL OXALATE remains US FDA's Preferred Term for this commodity. Donepezil oxalate bears US NLM identifiers UMLS ID C2828323 and NCI Concept Code C87489. SMILES: COC1CC2C(CC1OC)C(=O)C(C2)CC3CCN(CC3)CC4CCCCC4.C(=O)(C(=O)O)O.

UNSPSC 51141591 Donepezil oxalate is a Commodity code that nominally identifies a specific pharmaceutical active ingredient, but recent state and local procurement activity under this code does not focus on donepezil itself. Instead, issuing bodies are sourcing broader pharmaceutical and health-related products — naloxone, generic multi-source drugs and over-the-counter products, and prescription fulfillment services — through cooperative purchasing agreements and direct-to-manufacturer models. State and local buyers using this code include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions. The work involves procurement of finished pharmaceutical products for public health initiatives, supply chain management through authorized wholesalers, and exploratory contracting mechanisms to support prescription benefit programs serving state employees and covered populations.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option, with responses due July 26, 2023. The Texas Health and Human Services Commission posted Request for Information HHS0017013 in April 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program supporting self-insured state employee health plans and government agencies, with response deadline April 3, 2026. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and awards effective July 1, 2026. Vendors must comply with cGMP, Drug Supply Chain Security Act (DSCSA), FDA requirements, and maintain relationships with authorized wholesalers; MMCAP imposes a 3 percent administrative fee and performance penalties for non-compliance.